Zentalis Pharmaceuticals Llc


Prices are adjusted according to historical splits.

Zentalis Pharmaceuticals Llc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.92 billion
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Zentalis Pharmaceuticals Llc had its IPO on 2020-04-03 under the ticker symbol ZNTL.

The company operates in the Healthcare sector and Biotechnology industry. Zentalis Pharmaceuticals Llc has a staff strength of 156 employees.

Stock update

Shares of Zentalis Pharmaceuticals Llc opened at $24.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $24.36 - $25.02, and closed at $24.7.

This is a -1% slip from the previous day's closing price.

A total volume of 657,118 shares were traded at the close of the day’s session.

In the last one week, shares of Zentalis Pharmaceuticals Llc have slipped by -8.99%.

Zentalis Pharmaceuticals Llc's Key Ratios

Zentalis Pharmaceuticals Llc has a market cap of $1.92 billion, indicating a price to book ratio of 2.661 and a price to sales ratio of 0.

In the last 12-months Zentalis Pharmaceuticals Llc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-222856992. The EBITDA ratio measures Zentalis Pharmaceuticals Llc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Zentalis Pharmaceuticals Llc’s operating margin was 0% while its return on assets stood at -23.57% with a return of equity of -57.29%.

In Q2, Zentalis Pharmaceuticals Llc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Zentalis Pharmaceuticals Llc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-4.87 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zentalis Pharmaceuticals Llc’s profitability.

Zentalis Pharmaceuticals Llc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.24. Its price to sales ratio in the trailing 12-months stood at 0.

Zentalis Pharmaceuticals Llc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$621.44 million
Total Liabilities
$51.76 million
Operating Cash Flow
$72.93 million
Capital Expenditure
Dividend Payout Ratio

Zentalis Pharmaceuticals Llc ended 2024 with $621.44 million in total assets and $0 in total liabilities. Its intangible assets were valued at $621.44 million while shareholder equity stood at $523.14 million.

Zentalis Pharmaceuticals Llc ended 2024 with $0 in deferred long-term liabilities, $51.76 million in other current liabilities, 70000.00 in common stock, $-772111000.00 in retained earnings and $3.74 million in goodwill. Its cash balance stood at $266.56 million and cash and short-term investments were $552.99 million. The company’s total short-term debt was $2,335,000 while long-term debt stood at $0.

Zentalis Pharmaceuticals Llc’s total current assets stands at $563.93 million while long-term investments were $0.00 and short-term investments were $286.43 million. Its net receivables were $1.79 million compared to accounts payable of $12.31 million and inventory worth $8.22 million.

In 2024, Zentalis Pharmaceuticals Llc's operating cash flow was $72.93 million while its capital expenditure stood at $319000.

Comparatively, Zentalis Pharmaceuticals Llc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Zentalis Pharmaceuticals Llc stock is currently trading at $24.7 per share. It touched a 52-week high of $31.46 and a 52-week low of $31.46. Analysts tracking the stock have a 12-month average target price of $50.3.

Its 50-day moving average was $26.32 and 200-day moving average was $22.87 The short ratio stood at 28.25 indicating a short percent outstanding of 0%.

Around 273.4% of the company’s stock are held by insiders while 10208.7% are held by institutions.

Frequently Asked Questions About Zentalis Pharmaceuticals Llc

The stock symbol (also called stock or share ticker) of Zentalis Pharmaceuticals Llc is ZNTL

The IPO of Zentalis Pharmaceuticals Llc took place on 2020-04-03

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company’s products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.


1359 Broadway, New York, NY, United States, 10018